Mineralys Therapeutics Inc
MLYS45.600USD
+1.100+2.47%
Market hours （ET）Quotes delayed by 15 min
3.00BMarket Cap
LossP/E TTM
More Details of Mineralys Therapeutics Inc Company
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).
Mineralys Therapeutics Inc Info
Ticker SymbolMLYS
Company nameMineralys Therapeutics Inc
IPO dateFeb 10, 2023
CEOMr. Jon Congleton
Number of employees51
Security typeOrdinary Share
Fiscal year-endFeb 10
Address150 N. Radnor Chester Road
CityRADNOR
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code19087
Phone18883786240
Websitehttps://mineralystx.com/
Ticker SymbolMLYS
IPO dateFeb 10, 2023
CEOMr. Jon Congleton
Company Executives of Mineralys Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
663.52K
-2.23%
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
51.95K
-17.16%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Daphne Karydas
Ms. Daphne Karydas
Independent Director
Independent Director
--
--
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Dr. Brian Taylor (Bt) Slingsby, M.D., Ph.D.
Founder, Independent Director
Founder, Independent Director
--
--
Dr. Derek DiRocco, Ph.D.
Dr. Derek DiRocco, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jon Congleton
Mr. Jon Congleton
Chief Executive Officer, Director
Chief Executive Officer, Director
663.52K
-2.23%
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
588.24K
--
Mr. Adam Scott Levy
Mr. Adam Scott Levy
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
51.95K
-17.16%
Mr. Glenn P. Sblendorio
Mr. Glenn P. Sblendorio
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Alexander M. Gold, M.D.
Mr. Alexander M. Gold, M.D.
Independent Director
Independent Director
--
--
Dr. David M. Rodman, M.D.
Dr. David M. Rodman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Nov 7
Updated: Fri, Nov 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Catalys Pacific, LLC
11.79%
RA Capital Management, LP
9.70%
Samsara BioCapital, LLC
7.51%
SR One Capital Management, LP
4.14%
The Vanguard Group, Inc.
3.98%
Other
62.88%
Shareholders
Shareholders
Proportion
Catalys Pacific, LLC
11.79%
RA Capital Management, LP
9.70%
Samsara BioCapital, LLC
7.51%
SR One Capital Management, LP
4.14%
The Vanguard Group, Inc.
3.98%
Other
62.88%
Shareholder Types
Shareholders
Proportion
Venture Capital
33.14%
Investment Advisor
26.65%
Hedge Fund
19.68%
Investment Advisor/Hedge Fund
14.86%
Private Equity
5.26%
Individual Investor
1.82%
Research Firm
1.60%
Bank and Trust
0.16%
Pension Fund
0.13%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
315
76.75M
101.61%
+1.04M
2025Q2
287
68.74M
105.48%
+8.03M
2025Q1
278
68.91M
105.92%
+7.50M
2024Q4
230
53.93M
108.22%
-5.12M
2024Q3
214
51.53M
103.61%
-6.38M
2024Q2
197
51.29M
104.21%
-4.08M
2024Q1
188
49.20M
100.04%
-4.93M
2023Q4
172
42.00M
101.88%
-1.03M
2023Q3
140
43.25M
105.60%
+16.34M
2023Q2
116
41.91M
102.57%
+17.25M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Catalys Pacific, LLC
8.90M
11.79%
--
--
Jun 30, 2025
RA Capital Management, LP
7.32M
9.7%
+1.18M
+19.14%
Sep 04, 2025
Samsara BioCapital, LLC
5.67M
7.51%
--
--
Sep 04, 2025
SR One Capital Management, LP
3.13M
4.14%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.32M
3.07%
+283.58K
+13.93%
Jun 30, 2025
Capital International Investors
2.90M
3.84%
+2.90M
--
Jun 30, 2025
Andera Partners S.A.S.
2.77M
3.66%
-100.00K
-3.49%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.74M
3.62%
+532.75K
+24.18%
Jun 30, 2025
Integral Health Asset Management, LLC
2.70M
3.57%
+400.00K
+17.39%
Jun 30, 2025
Capital World Investors
2.90M
3.84%
+2.90M
--
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Simplify Health Care ETF
6.55%
Invesco Dorsey Wright Healthcare Momentum ETF
2.36%
Virtus LifeSci Biotech Clinical Trials ETF
1.83%
Invesco Dorsey Wright SmallCap Momentum ETF
0.54%
SPDR S&P Biotech ETF
0.31%
iShares Micro-Cap ETF
0.28%
ProShares Ultra Nasdaq Biotechnology
0.26%
Invesco Nasdaq Biotechnology ETF
0.25%
Optimize Strategy Index ETF
0.24%
Vanguard US Momentum Factor ETF
0.19%
View more
Simplify Health Care ETF
Proportion6.55%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion2.36%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.83%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.54%
SPDR S&P Biotech ETF
Proportion0.31%
iShares Micro-Cap ETF
Proportion0.28%
ProShares Ultra Nasdaq Biotechnology
Proportion0.26%
Invesco Nasdaq Biotechnology ETF
Proportion0.25%
Optimize Strategy Index ETF
Proportion0.24%
Vanguard US Momentum Factor ETF
Proportion0.19%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
